Explain this page
Arphra AIPlain-English read on Oruka Therapeutics, Inc.’s valuation06-10today
- Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?8d
- Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade10d
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update37d
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update37d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$6.93
-90.42% vs spot
Recommendation
Sell
3 of 3 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $149.50 (+106.66%)
Candlestick · 1Y
Open in chart workstation →ORKA
72.34+110.90%H 74.74L 31.00MA50 53.42MA200 —Avg vol 893K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.90% | +6.76% | +25.02% | +78.77% | +159.10% | +140.64% | +508.83% | +188.06% | +68.37% | -88.15% | -100.00% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$1.22M
10 txns
Net flow
−$1.22M
Aftermarket
LiveLast trade
$73.00
4 sh
Bid
$59.99
1 sh
Ask
$75.00
19 sh
Spread
$15.010
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $0 | -$29.58M | $-0.54 |
| Q3 Sep 2025 | $0 | -$30.28M | $-0.69 |
| Q2 Jun 2025 | $0 | -$24.57M | $-0.58 |
| Q1 Mar 2025 | $0 | -$21M | $-0.50 |
| Q4 Dec 2024 | $0 | -$33.39M | $-1.54 |
| Q3 Sep 2024 | $0 | -$28.62M | $-1.91 |
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?zacks.com·Jun 12, 2026
- Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Tradezacks.com·Jun 10, 2026
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·May 13, 2026
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·May 13, 2026
Recent analyst activity
DB- Jun 03, 2026GradeBuy → BuyH.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA)H.C. Wainwright
- Jun 02, 2026GradeOverweight → OverweightPiper Sandler on Oruka Therapeutics (ORKA): 'We remain bullish into a catalyst-rich year+'Piper Sandler
- Jun 02, 2026PT$180.00Piper Sandler on Oruka Therapeutics (ORKA): 'We remain bullish into a catalyst-rich year+'Piper Sandler
Peers
No peer list available for ORKA.
Total assets
$488.62M
Total debt
$1.93M
Cash & equiv
$46.94M
Operating CF
-$88.21M
Free cash flow
-$88.42M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Sandler Laura Lee officer: Chief Operating Officer | Sell | 600 | $41.81K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 300 | $21.19K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 947 | $66K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 1,636 | $111.88K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 5,064 | $351.55K | Jun 15, 2026 |
Klein Lawrence Otto director, officer: Chief Executive Officer | Sell | 1,729 | $120.49K | Jun 15, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $0 | -$122.05M | -$105.43M | $-2.31 | — |
| FY 2024 | $0 | -$88.12M | -$83.72M | $-4.99 | — |
| FY 2023 | $0 | -$7.3M | -$5.34M | $-4.44 | — |
| FY 2022 | $0 | -$9.84M | -$9.93M | $-8.27 | — |
| FY 2021 | $0 | -$19.34M | -$19.32M | $-16.68 | — |